These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15826590)

  • 61. [Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams].
    Korbal P; Mikołajczak A; Szymański W
    Ginekol Pol; 2003 Oct; 74(10):1154-9. PubMed ID: 14669411
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
    Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
    Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
    [No Abstract]   [Full Text] [Related]  

  • 64. Nirsevimab to reduce infant morbidity from respiratory syncytial virus.
    Abu-Raya B; Langley JM; Lavoie P
    CMAJ; 2024 Sep; 196(32):E1114-E1117. PubMed ID: 39353638
    [No Abstract]   [Full Text] [Related]  

  • 65. RSV infection and bronchiolitis: who qualifies for prevention?
    Prescrire Int; 2000 Dec; 9(50):173. PubMed ID: 11475495
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Palivizumab and RSV prevention.
    Lenney W
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960342
    [No Abstract]   [Full Text] [Related]  

  • 67. Palivizumab and RSV prevention.
    Carnegie C
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960341
    [No Abstract]   [Full Text] [Related]  

  • 68. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
    Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
    Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of palivizumab in primary practice.
    Perrin KM; Bégué RE
    Pediatrics; 2012 Jan; 129(1):55-61. PubMed ID: 22184649
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.
    Sáez-Llorens X; Moreno MT; Ramilo O; Sánchez PJ; Top FH; Connor EM;
    Pediatr Infect Dis J; 2004 Aug; 23(8):707-12. PubMed ID: 15295219
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
    Pollack P; Groothuis JR
    J Infect Chemother; 2002 Sep; 8(3):201-6. PubMed ID: 12373481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Ribavirin in the treatment of bronchiolitis caused by syncytial respiratory virus].
    Sánchez-Solís de Querol M; Castillo-Ochando F; Díaz-Torres M; Sayed-Sancho N; Sánchez-Flores F; Pajarón de Ahumada M
    An Esp Pediatr; 1997 Jul; 47(1):14-6. PubMed ID: 9290254
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.
    Goddard NL; Cooke MC; Gupta RK; Nguyen-Van-Tam JS
    Epidemiol Infect; 2007 Jan; 135(1):159-62. PubMed ID: 16753078
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan.
    Mori M; Kawashima H; Nakamura H; Nakagawa M; Kusuda S; Saji T; Tsutsumi H; Yokota S; Itoh S;
    J Infect Chemother; 2011 Apr; 17(2):254-63. PubMed ID: 20872156
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety of palivizumab in preterm infants 29 to 32 weeks' gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection.
    Groothuis JR
    Eur J Clin Microbiol Infect Dis; 2003 Jul; 22(7):414-7. PubMed ID: 12827537
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.